Balanced Portfolio - Take profit 2% CSL Limited (CSL)
Date: 24/1/2024
*** GENERAL AVICE ONLY***
CSL Limited (CSL) stands as a pioneering force in the biotechnology sector, dedicated to the creation and provision of ground-breaking medical solutions. With a mission to save and enhance lives, CSL focuses on developing life-saving medicines that are crucial for individuals facing critical health conditions. This global entity is not only deeply invested in the research and development of biopharmaceutical products but also excels in their manufacturing, marketing, and distribution. At the core of CSL’s operations are two key business divisions: CSL Behring and Seqirus. These segments epitomize CSL’s commitment to public health, underscoring their role in advancing medical science and improving patient outcomes worldwide.
PE: 64.85
Yield: 1.24%
Mkt Cap: $142B
CSL Limited (CSL) – Take profit 2%
CSL has reached the upper end of its trading range. In line with our commitment to optimizing returns and managing risks effectively, we are taking profit on the remaining 2% of our CSL position.
Entry: $242 | Exit: >$292 | Profit: 20.6%
Disclaimer: The recommendation given is general advice only. It does not take into account your personal objectives, financial situation, or specific needs. This information should not be your sole resource when making such decisions. We strongly recommend you to seek the advice of financial, taxation, and legal professionals before finalising any investment decisions.